SANOFI · Sanofi India Ltd · Biotechnology & Drugs
SANOFI · Sanofi India Ltd · Biotechnology & Drugs
As of 06 Nov close
52-week range
32.1% below 52-week high
52-week range: as of 06 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 16 Oct 2026
Revenue (latest Q)
₹438 Cr
Revenue YoY
PAT YoY
+20.1%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
8.2
P/S (TTM)
3.8
Sector P/E
33.6
Dividend yield
+4.2%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| SANOFI (this stock) | 24.2 | 8.2 | +17.9% | +39.2% | 0.02 | +4.2% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
stable
MF
9.14% (-0.12pp)
falling 3q
Insider trades
| Date | Insider | Type | Qty | Value |
|---|---|---|---|---|
| 24 Sept 2026 | Sanofi Healthcare India Private Limited | BUY | 35,00,000 | ₹1,068 Cr |
| 24 Sept 2026 | Hoechst GmbH | SELL | 35,00,000 | ₹1,068 Cr |
Bulk/block deals
| date | canonicalSymbol | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| 2026-09-24 | SANOFI | 3500000 | 1 | WEAK | BULK |
News timeline
- mediumcorporate actionthehindubusinessline.com· 24 Sept 2026, 11:28 pmSanofi Healthcare India buys 15.19% stake in Sanofi India
- mediumcorporate actioneconomictimes.indiatimes.com· 24 Sept 2026, 09:44 pmSanofi Healthcare buys 15.2% stake in Sanofi India for Rs 1,068 crore
- unknownthehindubusinessline.com· 09 Sept 2026, 07:15 amStocks to watch today: Enviro Infra, NLC India, Berger Paints, Sanofi India, Fusion Finance and others
- unknowneconomictimes.indiatimes.com· 09 Sept 2026, 06:00 amStocks in news: Biocon, Bank of Baroda, TCS, Sanofi India and Tata Capital
Concalls & investor presentations
AI-generatedKey takeaway: Sanofi India Limited held an Investor Conference Call on August 5, 2026, to discuss its financial results for the quarter and half year ended June 30, 2026. Management reported a strong performance in the diabetes business, achieving nearly 14% growth, driven by products like Toujeo and Soliqua. The company emphasized its market leadership in the diabetes segment, holding a 47% market share by value. Management also highlighted a 2% growth in overall performance compared to the previous year, attributing this to strategic partnerships and resource optimization. The call included discussions on the company's CSR initiatives, which aim to reach over 600,000 beneficiaries by year-end. Financially, the company reported a 19% increase in profit before tax for the quarter. However, management acknowledged challenges in the partnership business, particularly in the cardiovascular and CNS segments, and indicated ongoing efforts to improve performance in these areas.
The management highlighted strong growth in the diabetes segment while also addressing challenges in other areas.
Sourced from an exchange-filed transcript, dated 10 Aug 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Sanofi India Limited held an Investor Conference Call on February 26, 2026, to discuss its financial results for the year ended December 31, 2025. Management highlighted a year of transformation, focusing on modernizing its business model to achieve sustainable growth. Despite flat domestic sales, the company reported a 1% increase in profit before tax, driven by operational efficiency and a strong diabetes franchise. The diabetes segment, particularly the insulin products, showed growth, with Lantus maintaining a 31% market share in the basal segment. Management noted challenges in partnership sales, attributing a 2% decline to stock movement and competitive pricing pressures. They emphasized ongoing efforts in R&D and CSR initiatives, including community outreach programs. The call concluded with management reiterating their commitment to stabilizing partnerships and maximizing growth opportunities in the diabetes market.
The document presented both achievements and challenges faced by the company.
Sourced from an exchange-filed transcript, dated 05 Mar 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Sanofi India Limited's investor presentation detailed the company's strategic transformation aimed at sustainable and profitable growth. Management reported a flat domestic sales performance for 2025, with a 1% increase in profit before tax attributed to operational efficiency and a focus on the diabetes franchise. The presentation highlighted a new organization dedicated to enhancing the insulin franchise through customer-centric and AI-enabled capabilities. Key financial metrics included a total income of ₹18.726 billion for the year, with a 1% increase in profit before tax year-to-date. The company also emphasized its corporate social responsibility initiatives, reaching over 1.1 million beneficiaries through health awareness programs. Management noted a strategic focus on partnerships and digital outreach to expand market access, particularly in the diabetes segment. Overall, the presentation underscored a commitment to operational excellence and future-ready capabilities.
Management emphasized a strategic transformation and operational excellence driving growth.
Sourced from an exchange-filed presentation, dated 26 Feb 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedSanofi India Limited's FY2025 annual report highlights strategic initiatives focused on growth, innovation, and operational efficiency, with an emphasis on expanding manufacturing localization and leveraging the Sanofi Group's global supply network. The report underscores the company's commitment to stakeholder engagement, sustainability, and corporate governance. Notably, the company appointed two new Independent Directors, Mrs. Rajani Kesari and Mr. Siraj Azmat Chaudhry, effective April 1, 2026, following recommendations from the Nomination and Remuneration Committee. The report also details the demerger of the Consumer Healthcare business into a wholly-owned subsidiary, Sanofi Consumer Healthcare India Limited, effective June 1, 2024, with financial performance and cash flow data for the discontinued operations provided. The company maintains robust internal financial controls, with no material weaknesses identified, and has not accepted deposits from the public or granted loans, guarantees, or investments. Tax litigations and contingencies are disclosed as contingent liabilities amounting to ₹3,186 million, with management's assessment supported by independent consultants.
- Sanofi India Limited focused on growth, innovation, and operational efficiency in FY2025, leveraging global manufacturing networks.
- Two new Independent Directors, Mrs. Rajani Kesari and Mr. Siraj Azmat Chaudhry, were appointed effective April 1, 2026.
- The Consumer Healthcare business was demerged into Sanofi Consumer Healthcare India Limited, effective June 1, 2024.
- Contingent liabilities related to tax litigations and contingencies amount to ₹3,186 million as of December 31, 2025.
- No material weaknesses in internal financial controls were identified, and the company has not accepted public deposits or granted loans.
Key takeaway: Sanofi India Limited's FY2025 report highlights strategic growth initiatives, governance updates, and a significant contingent liability related to tax matters, with no material weaknesses in internal controls.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Default / Covenant Breach (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Default / Covenant Breach
1 occurrenceRecent (last 12 months)
The company has statutory dues under various acts (Income-tax, Central Sales Tax, Central Excise) with disputes pending in tribunals and courts, including amounts from 1998-2009 to 2022-2023, though no arrears over six months are outstanding.
Routine disclosures
Contingent Liability
2 occurrencesRecent (last 12 months)
The company has disclosed contingent liabilities of ₹3,186 million related to pending tax litigations as of December 31, 2025.
Earlier (1-3 years ago)
The company has pending legal cases and indirect tax litigations with a remote possibility of cash outflow, as per management's assessment.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
1.16% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).